# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian epithelial cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 535 results.
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Status: Not yet recruiting
Last Changed: Mar 10, 2020
First Received: Jan 23, 2020
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Ceralasertib, Placebo to match olaparib
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Recruiting
Last Changed: Mar 18, 2020
First Received: Aug 11, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fostamatinib and Paclitaxel
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Sep 04, 2018
First Received: Jul 16, 2018
Disease(s): Ovarian Cancer
Intervention(s): Apatinib
Locations: The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Status: Recruiting
Last Changed: Feb 20, 2020
First Received: May 03, 2019
Disease(s): Ovarian Cancer
Intervention(s): Palbociclib 125mg, Letrozole 2.5mg
Locations: Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil
Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil
AC Camargo Cancer Center, São Paulo, Brazil
Hospital Beneficência Portuguesa, São Paulo, Brazil
... and 3 other locations.
Engineered Immune Effectors Against Ovarian Cancer
Status: Recruiting
Last Changed: Sep 19, 2019
First Received: Dec 05, 2017
Disease(s): Ovarian Cancer
Intervention(s): OC-CTLs
Locations: Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Status: Recruiting
Last Changed: Apr 16, 2019
First Received: Apr 16, 2019
Disease(s): Ovarian Cancer
Intervention(s): anti-MESO CAR-T cells
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy
Status: Not yet recruiting
Last Changed: Feb 19, 2016
First Received: Feb 19, 2016
Disease(s): Ovarian Cancer
Intervention(s): Laparoscopy, Laparotomy
Genetically Modified T Cells Against Ovarian Cancer
Status: Recruiting
Last Changed: Mar 19, 2020
First Received: Jun 14, 2017
Disease(s): Ovarian Cancer
Intervention(s): OC-IgT cells
Locations: Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 10, 2019
First Received: Jan 10, 2019
Disease(s): Ovarian Cancer
Intervention(s): anti-MESO CAR-T cells, Fludarabine, Cyclophosphamide
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
Status: Recruiting
Last Changed: Mar 30, 2020
First Received: Nov 09, 2018
Disease(s): Advanced Ovarian Cancer
Intervention(s): Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Locations: Research Site, Concord, California, United States
Research Site, Foothill Ranch, California, United States
Research Site, Los Angeles, California, United States
Research Site, Oakland, California, United States
Research Site, Orange, California, United States
... and 220 other locations.